BioCentury
ARTICLE | Clinical News

OTX015: Interim Phase Ib data

April 21, 2014 7:00 AM UTC

Interim data from an open-label, European Phase Ib trial in patients with acute leukemia and other hematologic malignancies showed that once-daily 10, 20, 40 and 80 mg and twice-daily 40 mg doses of oral OTX015 led to no DLTs. In patients with acute leukemia, the MTD was not reached at the once-daily 80 mg dose or the twice-daily 40 mg dose. The MTD was also not reached at the once-daily 80 mg dose for patients with other hematologic malignancies, but Oncoethix said the MTD was exceeded at the twice-daily 40 mg dose in patients with other hematologic malignancies. Grade 3/4 adverse events were reversible thrombocytopenia, neutropenia, diarrhea and elevated transaminases. ...